Mouse experiments and human treatment databases showed CD4+ T cells can eliminate cancer cells that have lost MHC I, a route tumors use to evade CD8+ “killer” T cells.
The finding overturns the long-held split in which MHC I drives CD8+ responses and MHC II drives CD4+ responses, expanding MHC I’s role in T-cell immunity.
Researchers traced the CD4+ attack to ferroptosis—an iron-dependent cell-death pathway—and saw the same mechanism in mouse graft-versus-host disease models, where CD4+ cells damaged intestinal tissue despite missing MHC I.
Published in Nature Immunology, the work could sharpen cancer immunotherapy and help limit harmful immune reactions, though the team said clinical studies are still needed because the core experiments were in mice.
If 'helper' T cells are also killers, what other fundamental rules of our immune system have we misunderstood?
This mechanism drives cancer cell death and GVHD. Could a single drug be developed to treat these different diseases?
Ferroptosis kills cancer but also CAR-T cells. How can we control this double-edged sword for better patient outcomes?
Paradigm Shift in Cancer Immunotherapy: 2026 Discovery Reveals CD4+ T Cells Directly Kill MHC I-Deficient Tumors via Ferroptosis
Overview
A groundbreaking study published in 2026 has overturned a long-standing belief in immunology that only CD8+ T cells can directly kill tumor cells expressing MHC class I molecules. Researchers discovered that CD4+ T cells can also directly eliminate tumor cells, especially those lacking MHC class I—a common way cancers evade the immune system. This finding not only challenges previous dogma but also opens new possibilities for cancer treatment, as it suggests CD4+ T cells can target tumors that were previously considered resistant to immunotherapy. The discovery paves the way for innovative therapies and a broader understanding of immune defense against cancer.